Business
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nAchieved record quarterly and full-year total revenue of $86 million and $292 million, respectively\n\n\nProvides full year 2026 total revenue guidance range of $375 million to $390 million\n\n\nHosts conference call and webcast today at 8:30 a.m. ET\n\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026.\n\n\n\"Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self-funding, sustainable biopharmaceutical company,” said John Shannon, CEO. “As we enter 2026 from this position of strength, we remain focused on driving continued rapid revenue growth, the timely execution of XP-8121's ongoing development leading into the start of its Phase 3 clinical trial, and the judicious deployment of capital to further strengthen our business outlook in order to maximize long-term value for shareholders.\"\n\n\n\"Our exceptional results in 2025 reflect the strength of our business and set the stage for our future,” said Steve Pieper, CFO. \"As we look ahead to 2026, we will build on the strong momentum across our enterprise and expect total revenue to range from approximately $375 million to $390 million, representing more than 30% growth at the midpoint. This outlook will further strengthen our balance sheet, which will create even more financial flexibility to drive value in both the near and long term.\"\n\n\nFourth Quarter 2025 Highlights\n\n\n\n\n\nThree months ended December 31,\n\n\n\n\n\n\n \n\n\n\n\n\n\nChange\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n2025\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2024\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nProduct revenue (in thousands):\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nRecorlev\n\n\n\n\n\n\n$\n\n\n\n\n\n\n45,334\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n22,614\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n22,720\n\n\n\n\n\n\n \n\n\n\n\n\n\n100.5\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nGvoke\n\n\...